INL1

Innolife Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	INL1
Sponsor	Innolife Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INL1 CI brief — competitive landscape report
INL1 updates RSS · CI watch RSS
Innolife Co., Ltd. portfolio CI